- Faculty
- Health
- In the News
Ph II Radium-223 Dichloride in Combination w/ Paclitaxel in Patients w/ Bone Metastatic Breast Ca
Ritesh Parajuli
A Study On:
- Breast
Status:
- Open
Eligibility
Adults
Interested in joining this trial?
Official Title
Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer
Details
This phase II trial studies how well radium-223 dichloride and paclitaxel work in treating patients with advanced breast cancer that has spread to the bones. Radium-223 dichloride is a radioactive drug that behaves in a similar way to calcium and collects in cancer that has spread to the bones (bone metastases). The radioactive particles in radium-223 dichloride act on bone metastases, killing the tumor cells and reducing the pain that they can cause. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving radium-223 dichloride and paclitaxel may work better in treating patients with metastatic breast cancer compared to paclitaxel alone
Eligibility
You can join if...
Inclusion Criteria:-Women or men with metastatic breast cancer with two or more bone metastases identified by technetium Tc-99m (99mTc) bone scintigraphy and/or computed tomography (CT), at least one of these bone lesions must not have been treated with prior radiation therapy
-A diagnosis of breast cancer must have been histologically or cytologically confirmed at any time point
Exclusion Criteria:
-Patients with peripheral neuropathy > grade 1
-Patients who have not recovered from adverse events (AEs) due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia
-Prior therapy with radionuclides (e.g., strontium, samarium, rhenium, radium)
Get in touch with our study team
News & Events
UCI Health enrolls patient in first U.S. study of medical device for erectile dysfunction Sickle cell disease treatment nearing FDA approval - Faculty
- Health
- In the News
His GERD is now a distant memory - Faculty
- Health
- In the News